▶Pfizer's revenue from its COVID-19 products is in steep decline, with projections falling from $8 billion in 2024 to approximately $5 billion in 2026, and Q4 2025 revenues for the franchise dropping 40% year-over-year.Apr 2026
▶The company is making a significant strategic bet on the obesity drug market, acquiring MetSara for over $10 billion after a bidding war and estimating the total addressable market could reach $150 billion.Apr 2026
▶Pfizer is executing a major cost-cutting initiative, targeting $7.2 billion in net savings by the end of 2026, with artificial intelligence cited as a key enabler for achieving these reductions without impacting top-line revenue.Apr 2026
▶While overall 2025 revenue declined, Pfizer's non-COVID business is a source of strength, growing 6% operationally for the full year, driven by a portfolio of recently launched and acquired products that generated $10.2 billion.Apr 2026
▶Regarding financial health, one view highlights a 50% stock price decline and disappointing 2024 guidance, while company executives point to underlying strength shown by 6% ex-COVID operational growth in 2025 and a $9.8 billion return to shareholders.Apr 2026
▶On strategic execution, an expert points to a past failure where a divested drug became a multi-billion dollar asset for Roivant, suggesting portfolio mismanagement. Conversely, Pfizer executives tout current successes, like the $10.2 billion revenue from new products and the Seagen acquisition progressing ahead of expectations.Apr 2026
▶The company's future outlook is contested. Analysts express concern that growth is 'heavily dependent' on the high-risk MetSara acquisition. In contrast, Pfizer's leadership projects stable revenue for 2026 and 4% core business growth, supported by a plan to initiate 20 Phase 3 programs.Apr 2026
Not enough data for timeline
Sign up free to see the full intelligence report
Get started free